Bariatric surgery can reverse Type 2 Diabetes in severely obese people, reducing or eliminating the need for medications, and improve other serious health problems such as high blood pressure and sleep apnea, but it still remains to be determined which patients with type 2 diabetes will benefit most from surgery.
Do individuals who are moderately obese also benefit from surgery? And what is the duration of improvement in diabetes after surgery? Is it lifelong? Does having surgery change the risk of complications from diabetes?
Those are precisely the kinds of questions that a new study known as ARMMS-T2D (Alliance of Randomized Trials of Medicine versus Metabolic Surgery in Type 2 Diabetes) will tackle over the next five years, thanks to an award from the National Institutes of Health (NIH).
The research is being conducted at institutions in the ARMMS-T2D consortium, composed of Cleveland Clinic, Joslin Diabetes Center, University of Pittsburgh and the University of Washington. The coordinating center is Cleveland Clinic.
The ARMMS-T2D study is a follow-up effort from four smaller-scale, randomized controlled trials conducted at these institutions, including SLIMM-T2D (Surgery or Lifestyle with Intensive Medical Management in the Treatment of Type 2 Diabetes) conducted by Joslin and Brigham and Women’s Hospital.
The SLIMM-T2D study examined whether gastric surgery (both band and bypass) or an intensive program of medical and lifestyle management (Why WAIT?) is more effective for the treatment of type 2 diabetes in overweight or mildly obese patients with type 2 diabetes. Data from this study have demonstrated that surgery is more effective in controlling diabetes than medical and lifestyle management, but longer-term information is needed.
You can read the other half of this great article on EureAlert here: http://bit.ly/2nhtGrZ